Back to School: How biopharma can reboot drug development. Access exclusive analysis here

JPM jolt

Gainers, decliners in the wake of 2018 J.P. Morgan Healthcare Conference

Fifteen biotechs that presented at the 2018 J.P. Morgan Healthcare Conference posted gains of at least 15%, with Ablynx N.V. (Euronext:ABLX; NASDAQ:ABLX) leading the risers after announcing that its board rejected two unsolicited acquisition proposals from Novo Nordisk A/S (CSE:NOVOB; NYSE:NVO).

On Dec. 22, Novo proposed to acquire Ablynx for €30.50 per share,

Read the full 534 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers